The plate was certainly full of data from biotech binary events released over the last week. Given the plethora of news, we’ll break it down into short and sharp summaries of our top ten events for the week.
La Jolla Pharmaceutical Company (NASDAQ: LJPC) shares surged to close the week up 74% to $34.53 after it announced that it met the primary endpoint in its Phase 3 ATHOS-3 trial of LJPC-501 in patients with catecholamine resistant hypotension (CRH). Key secondary endpoint data were not disclosed.
Kite Pharma, Inc., (Nasdaq:KITE) met the primary endpoint in its ZUMA-1 for its lead CAR-T candidate, axicabtagene ciloleucel (KTE-C19), in patients with chemorefractory aggressive B-cell non-Hodgkin lymphoma (NHL). After six months 31% of diffuse large B-cell lymphoma (DLBCL) patients showed a complete response. Shares closed the week up 38% to $72.53.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) shares closed the week up 29% to $4.81 after it announced on Wednesday that it met complete and partial remission endpoints in its Phase 2b AURA-LV (AURA) trial in lupus nephritis. 49% of patients obtained a complete response compared with 24% on placebo with no additional deaths.
Dynavax Technologies Corporation (NASDAQ:DVAX) shares closed up 54% for the week to $6.25 following receipt of a PDUFA date of August 10, 2017 for the resubmission of its Complete Response Letter (CRL) for HEPLISAV-B, a vaccine against hepatitis B infection.
NeuroDerm Ltd. (Nasdaq:NDRM) met key endpoints in its Phase 2 trial of ND0612H, in patients with advanced Parkinson's disease. Shares closed the week up 23% to $28.95.
Puma Biotechnology Inc (NASDAQ:PBYI) shares lost 14% to $32.80 on Thursday after news that Roche (OTCQX: RHHBY) met the primary endpoint in its Phase 3 APHINITY trial of study of Perjeta and Herceptin and chemotherapy. Puma is developing neratinib and chemotherapy against Herceptin.
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that it did not achieve the primary or secondary endpoints in its Phase 3 trial of ataluren in cystic fibrosis. Shares closed down 20% to $10.58 on Thursday.
Juno Therapeutics, Inc. (NASDAQ: JUNO) shut up shop with its CAR-T program of JCAR015. Shares closed the week at $21.61, down 17% from Wednesday’s close.
SCYNEXIS Inc (NASDAQ:SCYX) shares closed down Friday by 17% to $2.70 following news that the FDA has placed a clinical hold on intravenous (IV) SCY-078 following mild-to-moderate thrombotic events in healthy patients.
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) actually finished the week in the green but lost 16% on Friday to $11.63 following news that it will not meet the primary endpoint in its Phase 2 SOPRA trial of selinexor in relapsed/refractory acute myeloid leukemia (AML).
Upcoming Catalysts below for the next month: